RayzeBio radiopharmaceutical therapeutics company with its main program in a Phase 3 clinical trial. Co.'s main drug candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225 (Ac225), to tumors overexpressing somatostatin receptor type 2. RYZ101 consists of DOTATATE, a peptide binder, and a chelator, bound to Ac225. Co. is enrolling patients in a registrational Phase 3 clinical trial of RYZ101 for the treatment of gastroenteropancreatic neuroendocrine tumors in patients who have experienced progression of their cancer following treatment with Lu177 therapy. The RYZB YTD return is shown above.
The YTD Return on the RYZB YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether RYZB YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RYZB YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|